The current UNAIDS strategy calls for an end to HIV-related discrimination and fewer than 500,000 annual deaths from AIDS. Out of ten highlighted targets within the strategy, three center on prevention tools. Excerpted from AVAC Report 2016: Big Data, Real People.
UNAIDS 2016-2021 Strategy: What Does it Say about Prevention?
Key Population and Data Gaps
In too many countries and communities around the world key populations, including gay men and other men who have sex with men (MSM), transgender women, sex workers and people who inject drugs are subject to what Johns Hopkins researcher and advocate Stefan Baral terms “the data paradox”, meaning there “there is the least amount of data characterizing the needs of gay men and other MSM in the most stigmatizing settings.”
This graphic was excerpted from AVAC Report 2016: Big Data, Real People.
Gender Binaries and Competition for Resources
In the past year, as focus has rightly been placed on the needs of adolescent girls and young women, some stakeholders have suggested that men are being left behind. The offers a perfect example of data that prompt counterproductive action. Men aren’t being left behind. Both men and women, and boys and girls, are underserved in different ways.
This graphic was excerpted from AVAC Report 2016: Big Data, Real People.
Unnecessary Confusion on Hormonal Contraception and HIV: WHO must act now
The question of whether specific contraceptive methods, particularly the injectable progestogen-only method known as DMPA or Depo-Provera, affect women’s risk of HIV is complex and, for the moment, unanswered. And the WHO has added to the complexit with a layer of completely preventable confusion.
This graphic was excerpted from AVAC Report 2016: Big Data, Real People.
Key Barriers to Women’s Access to HIV Treatment: Making ‘Fact-Track’ a Reality
It is essential to understand the barriers to and facilitators of women’s access to ART, so that individual choices about when and whether to start, and continue with, treatment translate into positive mental and physical health outcomes for the woman, as well as benefiting public health.
In this review, socio-structural factors were explored at macro-, meso- and micro-levels in order to better understand the experiences women living with HIV have of treatment availability and their decision-making around uptake, and to assess how treatment programmes affect their lives. Removing barriers and changing policies and programmes to align with best practices will contribute substantially to efforts for the achievement of global goals such as the ‘90-90-90’ UNAIDS ‘Fast-Track’ targets.
Microbicides by the Numbers: Science, products, money and more
The term “microbicide” refers to substances being studied that could be used in the vagina and/or rectum to reduce the risk of HIV infection via sexual exposure. There are no licensed microbicides available today. Simple, easy-to-use microbicides would help these individuals take control of their own health—while offering people everywhere an additional, needed option. The graphics below represent key facts about the microbicide field.
MPT Products in the Pipeline: Selected highlights
This table shows which MPTs are further along in testing for both sustained-release and on-demand products. Women will have different needs and preferences throughout their lives. An array of different types of products is key to meeting the varying needs of different women. Excerpted from the MPTs factsheet.
Progress Toward an Vaccines
This one-page infographic from NIAID highlights challenges and progress in the search for a vaccines, and also includes brief descriptions of some of the approaches to vaccine development that scientists are exploring today.
Vaccines Clinical Trials Snapshot
Excerpted from our quick, colorful and comprehensive vaccines research four-pager, the centerspread tracks the current status and future possibilities of all potential vaccines approaches being test. The centerspread also has a list of what advocates’ should be on the lookout for.
bNAb Targets on HIV
Scientists have mapped the shape and structure of bNAbs and identified points of contact and binding with the envelope trimer, shown in this graphic. Understanding the shape of the binding sites for bNAbs is key to vaccine development.